|Chennai||Rs. 27770.00 (-0.14%)|
|Mumbai||Rs. 29200.00 (2.31%)|
|Delhi||Rs. 27900.00 (-0.36%)|
|Kolkata||Rs. 28270.00 (1%)|
|Kerala||Rs. 27050.00 (-0.37%)|
|Bangalore||Rs. 27550.00 (1.66%)|
|Hyderabad||Rs. 27770.00 (-0.14%)|
Britain's GlaxoSmithKline PLC says it has completed its $3.6 billion acquisition of U.S. biotech company Human Genome Sciences.
In a statement Friday, the pharmaceutical and consumer goods group says all outstanding shares were bought for $14.25 each in cash.
Human Genome Sciences, based in Rockville, Md., agreed to the acquisition last month after GSK raised its bid price from $13 a share.
Under the agreement, GSK gains full ownership of two experimental drugs plus Human Genome's only marketed medicine, Benlysta. That's the first new drug approved in about 50 years for lupus, a chronic immune disorder.
GSK expects the deal to add to core earnings from next year and to produce at least $200 million in cost savings by 2015.